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Background. Interaction between the coagulation and inflammation systems plays an important role in the development of
acute respiratory distress syndrome (ARDS). Anti-coagulation is an attractive option for ARDS treatment, and this has
promoted development of new antibodies. However, preclinical trials for these antibodies are often limited by the high cost
and availability of non-human primates. In the present study, we developed a novel alternative method to test the role of a
humanized anti-tissue factor mAb in acute lung injury with transgenic mice. Methodology/Principal Findings. Human tissue
factor knock-in (hTF-KI) transgenic mice and a novel humanized anti-human tissue factor mAb (anti-hTF mAb, CNTO859) were
developed. The hTF-KI mice showed a normal and functional expression of hTF. The anti-hTF mAb specifically blocked the pro-
coagulation activity of brain extracts from the hTF-KI mice and human, but not from wild type mice. An extrapulmonary ARDS
model was used by intestinal ischemia-reperfusion. Significant lung tissue damage in hTF-KI mice was observed after 2 h
reperfusion. Administration of CNTO859 (5 mg/kg, i.v.) attenuated the severity of lung tissue injury, decreased the total cell
counts and protein concentration in bronchoalveolar lavage fluid, and reduced Evans blue leakage. In addition, the treatment
significantly reduced alveolar fibrin deposition, and decreased tissue factor and plasminogen activator inhibitor-1 activity in
the serum. This treatment also down-regulated cytokine expression and reduced cell death in the lung. Conclusions. This
novel anti-hTF antibody showed beneficial effects on intestinal ischemia-reperfusion induced acute lung injury, which merits
further investigation for clinical usage. In addition, the use of knock-in transgenic mice to test the efficacy of antibodies
against human-specific proteins is a novel strategy for preclinical studies.
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INTRODUCTION
One of the important features and major underlying mechanisms
of acute lung injury (ALI) and its severe form acute respiratory
distress syndrome (ARDS) is the intensive inflammatory response
[1]. Evidence from animals and human studies indicates that
alveolar and interstitial coagulation disorder and fibrin deposition
are the hallmarks of early phase ALI/ARDS and other
inflammatory situations in the lung, including pneumonia [2],
sepsis [3,4], and ventilator-induced lung injury [5,6]. Coagulop-
athy not only adds another pathological feature to ALI/ARDS,
but also leads to inflammatory signals through the activation of
protease-activated receptors (PARs) [7,8,9], indicating an exten-
sive cross-talk and reciprocal amplification between coagulation
and inflammatory cascades [10].
Recently, increased attention has been paid in both experimental
and clinical research of ALI/ARDS to the interplay between
coagulation and inflammation[11,12].Anticoagulanttherapies were
developed and tested in animals and humans. An infusion of
activated protein C showed a beneficial effect on the mortality in
patients with severe sepsis [13], supporting the role of an anti-
coagulant therapy to treat inflammation. Since tissue factor (TF) is a
key initiator of the coagulation cascade and plays a critical role in
inflammation as well, anti-TF therapy is another attractive
anticoagulant strategy. Several reagents against the TF complex at
sequential steps in its assembly, including a competitive inhibitor of
Factor VIIa and an antibody to the Factor X binding site on TF,
were tested in an E. coli sepsis model in baboons [4,14,15]. TF
blockadehasshownprotectiveeffectswhenadministeredattheonset
of sepsis and given as a rescue therapy, decreasing systemic
inflammation, preventing fibrinogen depletion, and attenuating
injury to the lung, kidney, and other organs [4,14,15]. These
promising results support further development of new molecules
targeting coagulation pathways for clinical applications.
Currently, non-human primates are generally the best pre-clinical
models to test efficacy of antibodies against human proteins.
However, these models are often limited by their high cost and
animal availability. In the present study, we tested a humanized anti-
hTF monoclonal antibody (CNTO859) in a clinically relevant ALI
model induced by intestinal ischemia-reperfusion (IIR). However
instead of using non-human primates, we developed human TF
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instead of murine TF (mTF). CNTO859 treatment significantly
reduced IIR-induced lung injury, attenuated alveolar fibrin
deposition and inflammatory responses in the lung. This novel
antibody and the transgenic approach against human genes to
conduct pre-clinical studies in mice merit further investigations.
METHODS
hTF-KI transgenic mice and anti-hTF monoclonal
antibody, CNTO859
Generation of hTF-KI transgenic mice has been previously
described [16]. Briefly, the first two exons of murine TF gene was
replaced in-frame by human TF cDNA. As a result, expression of
mTF was completely disrupted and hTF was expressed under the
control of mTF promoter. Chimeric mice derived from targeted
129SvBrd embryonic stem cells were bred with C57BL/6 mice to
produce hTF/mTF heterozygous mice and the breeding colony was
established by further backcrossing with C57BL/6 mice. hTFKI
homozygous mice (hTF/hTF) and wild type littermates used in this
study were derived from breeding N2 heterozygous mice.
The anti-hTF monoclonal antibody, CNTO859, was geneti-
cally engineered by grafting the complementarity–determining
regions of a murine anti-hTF antibody, TF8-5G9, onto a human
immunoglobulin G4 frame. The antibody consists of 5–10%
murine and 90–95% human proteins [17].
Testing of hTF activity in transgenic mice
Pro-coagulant activity of hTF expressed in the transgenic mice was
tested using a one-stage clotting assay with brain homogenate in
comparison with that in wild type mice and in human brain tissue
(ILSbio, Chestertown, MD). Approximately 25 mg brain tissues
were homogenized in Hanks Balanced Salt Solution using Fast-
prep protein isolator tubes (Bio 101 Systems, Qbiogene, Carlsbad,
CA). Brain homogenates were frozen at 280uC immediately after
isolation, and were diluted 1:100 prior to use. The total protein
was measured at OD280 to determine concentration. Citrated
human plasma (100 ml) was incubated with increasing concentra-
tions of brain homogenate (200 ml and 10 mM CaCl2) and the
clotting time was recorded using Organon Teknika Coag-A-mate
XM [18]. All samples were tested in duplicate. The data were fit to
a hyperbolic curve to determine an EC50 (0.1 mg/ml for human
and hTF-KI mouse brain extracts, 0.4 mg/ml for wild type
littermate mouse extract).
We also used this assay to determine the inhibition efficacy and
specificity of CNTO859 on human TF activity by incubating the
brain extracts with increasing concentrations of either the
CNTO859 or an anti-murine TF mAb. The changes of clotting
time were recorded for comparison.
Intestinal ischemia reperfusion-induced acute lung
injury
Acute lung injury was induced by intestinal ischemia-reperfusion as
previously described [19,20] with modification. Briefly, male hTF-
KI mice (6–8 weeks, 25–30 g) were anesthetized with 5% isoflurane.
A tracheostomy cannula for mouse (H. Sachs Elektronik, March-
Hugstetten, Germany) was inserted into the trachea, and animals
were ventilated with a volume control ventilator (Inspira Advanced
Safety Ventilator, Harvard Apparatus, St. Laurent, Canada) at a
tidal volume of 6 ml/kg, inspiratory/expiratory ratio 1:2 and a
frequency of 140 breaths/min (FiO2 100%). Anesthesia was
maintained with 1.5% isoflurane and body temperature was
maintained at 37uC throughout the experiment. A midline
laparatomy was performed and the superior mesenteric artery was
identifiedandoccludedbelowtheceliactrunkwithanarterialmicro-
clamp (Mizuho Ikakogyo, Tokyo, Japan). Intestinal ischemia was
confirmed by paleness of the jejunum and ileum. After 45 min of
ischemia period, reperfusion was initiated by removal of the clamp
and confirmed by the color recovery of the intestine. Pre-warmed
(37uC) saline (0.5 ml) was instilled into the peritoneal cavity before
closed with a suture. At 10 min after the onset of reperfusion, hTF-
KImicewere randomizedinto2 groupstreated with eitheranti-hTF
mAb (CNTO859, 5 mg/kg) or saline at same volume (2.5 ml/kg)
throughthe jugularvein.Anesthesiaand ventilationwereterminated
after treatment. All animals were left on spontaneous breathing
during the 2 h of reperfusion, and then sacrificed by exsanguina-
tions. The blood, lung and intestine tissues, and bronchoalveolar
lavage (BAL) fluid were collected for further analysis. The
experimental protocol was approved by the Toronto General
HospitalAnimal CareandUse Committee.All micereceivedcarein
compliance with the Principles of Laboratory Animal Care
formulated by the National Society for Medical Research, and the
Guide for the Care and Use of Experimental Animals formulated by
the Canadian Council on Animal Care.
Histology and immunostaining
A stretch of intestine from the middle of IR-challenged area and
the right lungs were fixed in 10% formalin [20] and subjected for
histological examination and immunostaining. Hematoxylin and
eosin (H&E) staining was conducted with 5 mm tissue slides. The
lung injury was assessed with modified scoring systems by a
blinded pathologist according to the presence and extent of
interstitial cellular infiltration, alveolar wall edema, hemorrhage,
and atelectasis [21].
Immunostaining was performed for von Willebrand factor
(vWF) in the lung tissue. Briefly, the lung sections at 5 mm
thickness were blocked with 5% BSA (Sigma, Oakville, Canada) in
PBS for 30 min at 37uC after deparaffinization and dehydration.
The slides were then incubated with rabbit anti-vWF polyclonal
antibody (1:600 in 1% BSA, Dako, Mississauga, Canada) at 4uC
overnight. ABC System (Vector Laboratories, Burlingame, CA)
was used with a biotinylated goat anti-rabbit IgG (1:200) as the
secondary antibody and permanent red as the chromogen. The
specificity of the antibody was determined by replacing the
primary antibody with non-immunized IgG (Sigma).
Cell counting and protein in BAL fluid
After ligation of the right bronchus, BAL was performed in the left
lung by gently instilling and aspirating 0.25 ml saline through an
intratracheal tube 2 times. An aliquot (20 ml) of BAL fluid from each
animal was diluted with trypan blue (1:1) for total cell counting with
a hemocytometer. The rest of the fluid was centrifuged (4,000 g,
10 min), and a Bradford protein assay (Bio-Rad, Hercules, CA) was
conducted for the protein concentration in the supernatant [20].
Evans blue dye (EBD) assay and wet/dry (W/D) lung
weight ratio
The lower lobes of the right lungs were collected and dehydrated
at 60uC for 72 h in a vacuum oven. The wet and dry weights were
measured to calculate the W/D ratio. The EBD assay was
conducted as previously reported [20]. Evans blue dye (30 mg/kg,
Sigma) was administered via jugular vein 30 min before the
experiment terminated. After flushing with 10 ml of PBS, the
extravasation of EBD in the lung tissues was extracted, and
determined at 620 nm.
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Activities of hTF and plasminogen activator inhibitor-1 (PAI-1) in
the plasma were analyzed with a colorimetric assay according to
the manufacturer’s recommendations (American Diagnostica,
Stamford, CT). Fibrin deposition was stained with Martius Scarlet
Blue (MSB) using a standard protocol [22].
Electron microscopy
After IIR challenge, fresh lung biopsies were taken for electron
microscopy. The samples were fixed with 2% glutaraldehyde in
0.1 M sodium cacodylate buffer, post-fixed with 1% osmium
tetroxide in the same buffer, dehydrated in graded ethanol series,
and embedded in Spurr epoxy resin. The embedded tissues were
thin-sectioned, mounted on copper grids, and stained with uranyl
acetate and lead citrate, as previously described [19,20,23,24].
Photographs were taken with an FEI CM100 Electron Microscope
(FEI Company, Hillsboro, Oregon) equipped with a Kodak
MegaPlus digital camera.
Cytokine/chemokine measurement
Tumor necrosis factor a (TNFa), interleukin (IL)-6, IL-10, monocyte
chemoattractant protein-1 (MCP-1), and Interferon-c (IFN-c)i n
BAL fluid and lung tissue homogenates were measured using a
mouse inflammation kit of cytometric bead array according to the
manufacture’s instruction (BD Bioscience, Mississauga, Canada)
[25]. In brief, an aliquot of 50 ml sample was incubated with 50 mlo f
mixed beads coated with capturing antibodies specific for the
respectivecytokines and50 ml of PE-conjugateddetection antibodies
for 2 h at room temperature in dark. The beads were washed by
adding 1 ml of wash buffer and centrifugation, and then re-
suspended in 300 ml of wash buffer. The distinct fluorescence
intensities of beads were determined with a flow cytometer, and the
data acquired were converted to the concentrations of the cytokines
using BD CBA software (Becton Dickinson).
Terminal transferase dUTP nick end labeling
(TUNEL) staining
The lung cell death was assessed by TUNEL staining with In Situ Cell
Death Detection Kit (Roche, Penzberg, Germany) following the
manufacture’s instruction [20]. Briefly, after deparaffinization and
dehydration the slides were permeabilized with 10 mg/ml proteinase
K in 10 mM Tris/HCl (pH 7.4) for 15 min, and stained with
Tetramethylrhodamine (TMR)-labeled TUNEL-positive nucleotides
and counterstained with Hoechst (Pierce) for 10 min. Slides pre-
treatedwithDNase(3,000 U/mlin40 mMTris-HCl,pH 7.5,1 mg/
ml BSA) were served as a positive control. Slides for negative control
were incubated with the label solution without terminal transferase.
The TUNEL-positive cells were quantified from 10 optical fields
(400x) randomly chosen from each slide (n=4 animals/group).
Caspase 3 activity assay
Caspase 3 activity in the lung tissues was determined by measuring
the fluorescence of cleaved caspase 3 substrate as described
[19,24,26]. Lung homogenate containing 200 mg of total protein
was mixed with 125 mM fluorogenic substrate (Ac-DEVD-AMC,
Chemicon, Temecula, CA) in a 96-well plate. The plate was
incubated at 37uC for 60 min and the fluorescence intensity
(excitation of 360 nm and emission of 460 nm) was monitored
with a CytoFluor multi-well plate reader (PerSeptive Biosystems
Series 4000, Framingham, MA). The enzyme activity was
calculated against a standard curve generated with recombinant
caspase 3 (Chemicon). Tissue lysates from hypothermic preserved
rat donor lungs [24] were used as positive controls for the assay.
Statistical Analysis
Statistical software SPSS version 11.5 (SPSS, Chicago, IL) was used
for data analyzing. Data are presented as mean6standard deviation
(SD). All parametric data were analyzed with un-paired two-tailed t-
test. Non-parametric data (lung injury scores) were analyzed with
Kruskall-Wallis test. P value ,0.05 is defined as significant.
Figure 1. Human tissue factor is functionally expressed in hTF-KI
transgenic mice, and effectively and specifically inhibited by the
anti-hTF mAb, CNTO859. Pro-coagulant activity of TF in brain extracts
from either hTF-KI or wild type (WT) mice, or from human brain tissue
was measured with a one-stage clotting assay, and a similar
prothrombin time was seen in all brain extracts, indicating a functional
replacement of mTF by hTF expressed in the hTF-KI mice (A). Anti-hTF
antibody, CNTO859, dose-dependently inhibited TF pro-coagulant
activity in the brain extracts from hTF-KI mice and human, but not
wild type mice (B). The experiments were repeated three times, and
representative data from one experiment are shown.
doi:10.1371/journal.pone.0001527.g001
Anti-hTF Therapy in ALI
PLoS ONE | www.plosone.org 3 January 2008 | Issue 1 | e1527RESULTS
Human tissue factor maintains normal coagulant
activity in transgenic mice
To test anti-TF therapy against hTF in vivo, we used the hTF-KI
mice generated by replacing a portion of mTF gene with the open
reading frame of hTF. The hTF-KI mice have a similar life span
without abnormal pathology in comparison with wild type
animals. The tissue distribution and expression levels of hTF in
transgenic mice were similar to that of mTF in wild type mice, and
no mTF expression was detected in the transgenic mice [16]. The
brain extract of hTF-KI mice expressed hTF at 64 ng/mg protein,
a level comparable to that from the human brain extract at 80 ng/
mg protein. Tested with a one-stage clotting assay, the brain
Figure 2. Administration of anti-hTF mAb ameliorated intestinal ischemia-reperfusion (IIR)-induced acute lung injury in hTF-KI mice. IIR
challenged hTF-KI mice were treated with CNTO859 (5 mg/kg, i.v.) or saline. The representative histology (H&E, x400) from the intestine (A, B) and
lung (C, D) was shown. The lung injury was scored by a pathologist in a blind fashion (E) (& inflammatory cells infiltration; & alveolar wall edema; &
hemorrhage; atelectasis). % Lung injury scores of 4 categories were analyzed with Kruskall-Wallis test, n=4 animals/group, *: p,0.05. The pulmonary
permeability was determined by Evans Blue dye assay (F, G, H). Administration of CNTO859 also reduced the wet/dry lung weight ratio (I), albumin
concentration (J), and total cell counts (K) in the BAL fluid. Panels I-K: n=4 animals/group,*: p,0.05, un-paired t-test.
doi:10.1371/journal.pone.0001527.g002
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activity as that from wild type mice or human brain tissue (Fig. 1A).
These results suggest that hTF functionally substitutes mTF and
maintains a normal coagulant activity in the hTF-KI mice.
When the humanized monoclonal antibody, CNTO859, was
incubated with brain extracts from human or hTF-KI mice, it
inhibited coagulation dose-dependently as measured by prothrom-
bin time. The IC50 of CNTO859 for the hTF-KI brain extract was
similar to that for the human brain extract (0.045 vs. 0.05 mg/ml),
supporting that the hTF activity from both samples were
comparable. In contrast, this antibody had no effect on brain
extract from wild type mice (Fig. 1B). When an anti-mTF antibody
was used in the coagulation assay, an inhibition effect was found
only on brain extract from wild type mice, but not that from hTF-
KI mice (data not shown). These results further confirm the
specificity of CNTO859 on hTF and the substitution of mTF by
the hTF is complete in the hTF-KI mice.
Administration of CNTO859 ameliorated IIR-induced
ALI
A clinically relevant model of extrapulmonary ARDS has been used
to induce acute lung injury by intestinal ischemia-reperfusion in
C57BL/6 mice, and a high mortality rate was observed in these
studies during 4 h of reperfusion period when animals were
ventilated with oxygen [19,20]. It is known that C57BL/6 mice
are sensitive tohyperoxia [27]. In thepresent study,weused hTF-KI
mice,whichareofahybrid strainof129SvBrd(,20%)and C57BL/
6( ,80%). We first conducted a pilot study with a modified protocol,
in which animals were not subject to mechanical ventilation and
pure oxygen during the reperfusion period. There was no mortality
during the first 24 h of reperfusion (data not shown). The IIR
challenge induced a significant intestinal (Fig. 2A) and lung injury
(Fig. 2C) in hTF-KI mice, which are very similar to that in wild type
mice (data not shown) and as observed inour previous study [19,20].
These results suggest that hTF not only substituted mTF for
coagulation, but also may play a similar role in acute inflammatory
response related to acute lung injury.
We then used this modified IIR model to test the effects of anti-
hTF antibody in acute lung injury. The IIR-induced ALI in the hTF-
KI mice was characterized by increased pulmonary interstitial edema
(alveolar wall thickening), inflammatory cell infiltration, hemorrhage,
and atelectasis. Administration of anti-hTF antibody, CNTO859,
markedly ameliorated the IIR-induced ALI (Fig. 2D) in hTF-KI mice
with a significantly lower injury score (p,0.05, Fig. 2E).
One of the major features of ALI/ARDS is the increase in
pulmonary permeability [28,29]. A significant blockage of Evans
Blue Dye leaking was seen in the lung treated with CNTO859
(Fig. 2F–H). This effect was confirmed with lung wet/dry weight
ratio (Fig. 2I). The albumin content and total cell counts in the
BAL fluid were significantly lower in CNTO859-treated group
than in saline-treated group (Fig. 2J and 2K).
Anti-TF mAb treatment attenuated IIR-induced
coagulopathy
It is known that activation of TF can trigger a pro-coagulation
status, and lead to fibrin deposition in the lung. Administration of
CNTO859 significantly reduced both TF and PAI-1 activities in
the plasma (Fig. 3A and 3B), and dramatically attenuated the IIR-
induced alveolar fibrin deposition (Fig. 3C and 3D).
Endothelium damage is an important mechanism responsible
for the increase of pulmonary permeability [28,29]. vWF is an
endothelial specific marker, which is expressed mainly in larger
vessels in normal lung tissue [30,31]. In control animals, IIR
Figure 3. Anti-hTF mAb treatment attenuated IIR induced coagula-
pathy and protected pulmonary endothelium. Plasma TF and PAI-1
activities were determined as described in Methods. Administration of
CNTO859 significantly inhibited both TF (A) and PAI-1 (B) activities in
comparison with the saline treated control (*: p,0.05, n=4 animals/
group, un-paired t-test). The fibrin staining showed that CNTO859
ameliorated IIR-induced fibrin deposition (pink) in the alveoli (C, D). The
lung tissues were stained for vWF, a specific marker for endothelial
integrity. Weaker staining of vWF (pink) of endothelium in the
pulmonary vessels was noted in the saline control group (E). In
CNTO859 treated animals stronger vWF staining was observed in the
endothelium of pulmonary vessels (F). The pulmonary endothelial injury
was further examined with electron microscopy. IIR challenge led to
significant endothelial cell swelling (G), which was protected by
CNTO859 treatment (H).
doi:10.1371/journal.pone.0001527.g003
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pulmonary vessels (Fig. 3E). EM showed swelling of the cytoplasm,
nucleus, and mitochondria of the endothelial cells in micro
capillaries (Fig. 3G). In CNTO859 treated animals, vWF staining
was clearly stronger in the endothelial layer of larger pulmonary
vessels (Fig. 3F). The morphology of endothelial cells in pulmonary
capillaries was better preserved (Fig. 3H).
Anti-TF mAb treatment reduced inflammatory
response and cell death in the lung
Acute inflammatory response is a hallmark of ALI. CNTO859
treatment significantly reduced the levels of IL-6 and TNFa, and
MCP-1 in the lung tissue (Fig. 4A–C). The IL-6 levels in BALF
(Fig. 4D) were significantly reduced by CNTO859. However, the
levels of IL-10, an anti-inflammatory cytokine, did not change in
BALF (Fig. 4E), suggesting that the anti-inflammatory effect of
CNTO859 is not through up-regulation of IL-10.
In a previous study, we found that IIR induces alveolar
epithelial cell death [19]. In the present study, TUNEL positive
cells were found in the lung of hTF-KI mice after IIR challenge
(Fig. 5A), and they were significantly reduced by CNTO859
treatment (Fig. 5B and 5C). Caspase 3 is a key enzyme for
apoptotic cell death. CNTO859 treatment reduced caspase 3
activity in lung tissue homogenates (Fig. 5D).
DISCUSSION
Using transgenic mice to test efficacy of antibodies raised against
human proteins is an attractive and important concept. There are
only a few reports of using this strategy, thus, the results from the
present study provide more insights for further development of this
novel and useful model methodology.
Tissue factor, also named as thromboplastin, CD-142, and
coagulation factor III, is a single chain membrane glycoprotein
that functions as a receptor for Factor VII and VIIa and thereby
initiates the extrinsic pathway of the coagulation cascade in
response to vascular injury [32,33]. TF is generally localized in the
adventitial fibroblasts of blood vessels, and initiates a rapid
coagulation process when exposed to blood at the site of vessel
injury, thereby limiting blood loss and maintaining hemostasis
[34]. A compatibility study showed that hTF can bind to murine
Factor VIIa with high affinity to induce coagulation [35], while
mTF binds poorly to human Factor VIIa [35,36]. Our hTF-KI
transgenic mice showed expression of hTF at a physiological level
that is fully compatible to normal lifespan, coagulation function
[16] and similar inflammatory response upon IIR. The substitu-
tion or replacement of a murine protein with its human
counterpart is crucial for evaluating human-specific therapeutic
agents in murine models. The specificity and efficacy of the
humanized monoclonal antibody is also critically important. The
anti-hTF monoclonal antibody, CNTO859, specifically binds to
hTF [17], and inhibits the hTF activation in brain extracts from
human tissue and the hTF-KI transgenic mice, but not from wild
type littermate mice. It should be mentioned that we used the
antibody CNTO859 at a very high dose (20 mg/kg) in our
preliminary experiments, and observed no significant haemor-
rhage in the treated animals, indicating the safety of the antibody
(data not shown). These features are important for its potential
clinical application in the future.
ARDS is a multi-factorial syndrome with similar pathological
manifestations but distinct underlying mechanisms [1]. Anti-TF
therapy is attractive not only because of TF’s role in the coagulation
cascade, but also because of its pivotal role in the interplay with
inflammatory signaling. TF binding to Factor VIIa leads to
Figure 4. Anti-hTF mAb treatment reduced inflammatory response. Inflammatory cytokines were measured in the lung tissues and BAL fluid with a
cytometric bead array. The expression levels of IL-6 (A), TNFa (B), and MCP-1 (C) in the lung tissues were significantly reduced by CNTO859 in
comparison to saline group. In the BAL fluid CNTO859 also reduced the IL-6 levels (D), but the IL-10 level remained unchanged between the two
groups (E). Un-paired t-test was used, *: p,0.05, n=4 animals/group.
doi:10.1371/journal.pone.0001527.g004
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activates coagulation, thus resulting in thrombin generation, and
ultimately the clot formation. This complex has been demonstrated
as being critical for presenting Factor VIIa and Factor Xa to PARs
on the cell surface. Cleavage of PARs initiates the inflammatory
rather than coagulant activities of TF, including upregulation of
cytokine gene expression [7,9,14]. The requirement of TF as a co-
receptor for PAR1 and PAR2 activation is likely to be a key
determinant [37]. Recently, evidence showed the cytoplasmic
domain of TF is also involved in chemotaxis regulation [38].
In the present study, we used IIR to induce ALI in hTF-KI
mice. This is a clinically relevant model in which the severe
intestinal damage is the initial insult. The lung is the most
vulnerable remote organ after IIR, although cell death and
inflammation have been noted in other vital organs [20]. This
model has added value to other studies related to anti-TF
therapies. Our data show a significant attenuation of the lung
injury induced by IIR. The pulmonary permeability barrier
consists of capillary endothelial and alveolar epithelial cells.
Damage could occur on both sides of the alveolar walls during
ALI [39]. In the present study, administration of anti-hTF
antibody not only protected pulmonary endothelium from severe
injury, but also significantly reduced cell death in the lung tissue,
which mainly happens in alveolar epithelial cells upon IIR
challenge [20]. Thus, anti-TF therapy may have protective effects
on both endothelial and epithelial layers of alveolar walls. Ideally,
a humanized IgG, instead of normal saline should be used for
comparison with CNT0859, to exclude non-specific IgG effects.
Our studies were limited by the availability of this agent; the
results should be interpreted with caution.
The pulmonary level of TF expression has been found especially
high relative to other organs. The TF levels in pulmonary edema
fluid were found to be more than 100-fold higher than that in the
plasma in patients with ALI/ARDS, indicating a local hypercoa-
gulation status and tissue damages in the lung. The TF expression
and activity in lung alveolar epithelial cells was increased by pro-
inflammatory cytokines (e.g. TNFa and IL-1ß) [40]. We speculate
that local administration of an anti-TF antibody may have direct
benefits to ameliorate ALI, especially injury induced by intrapul-
monary insults, such as acid aspiration and lung transplantation.
The hTF-KI animals and the specific antibody may offer us a
useful model system to better characterize and understand the
effects of anti-TF therapy in ALI models induced by other insults,
such as sepsis, ventilator-induced lung injury, bacterial infection,
etc. Results from these studies may provide additional information
about the role of TF, as well as the potential therapeutic efficacy of
CNTO859. Using small animals, we will be able to collect critical
data prior to studies in non-human primates and clinical trials.
This strategy should be considered for the development of species-
specific therapeutic reagents for ALI/ARDS and other human
diseases.
In summary, this study demonstrated the potential therapeutic
effects of anti-TF strategy on ALI/ARDS with a new anti-TF
monoclonal antibody. The new experimental strategy of using
humanized antibody against human TF in transgenic mice offers a
useful tool for further assessing the anti-TF therapy in preclinical
trials for ARDS as well as other diseases related to the function of
tissue factor.
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